Group 1: AI Applications - The global AI competition is intensifying, with model iterations driving deeper application scenarios, and the focus is on whether significant capital expenditures by tech giants can lead to commercial applications [2][3] - The competitive landscape for AI applications is shifting from dominance by OpenAI to a more multipolar environment, with major players like Google and Meta integrating AI into their ecosystems [3] - In China, AI applications are experiencing a breakthrough, with major tech companies accelerating model iterations and application deployments, leading to a transformation from model landing to scenario monetization [5] Group 2: AI Computing Power - Overseas, major cloud service providers are maintaining high capital expenditures, with a projected increase of 67% in 2026, reflecting a strong demand for AI computing power [7][8] - In China, leading tech companies are increasing capital expenditures and accelerating the iteration of domestic large models, promoting the performance of domestic chips amid tightening supply from foreign sources [9] Group 3: Storage - The demand for storage is entering a new super cycle driven by AI training and inference needs, with AI servers consuming significantly more memory than traditional servers [11][16] - Supply constraints are expected to persist, leading to continued high prices for storage components, as major manufacturers shift production focus to advanced memory types [16] Group 4: Commercial Aerospace - Commercial aerospace is becoming a key battleground in US-China competition, with significant policy support and funding initiatives in both countries to accelerate industry development [19][21] - Domestic companies are achieving breakthroughs in satellite mass production and reusable rocket technologies, transitioning from technical validation to commercialization [22] Group 5: Humanoid Robots - Major overseas companies are ramping up production plans for humanoid robots, benefiting domestic component suppliers, with Tesla aiming for a production capacity of 500,000 units by 2026 [27][30] - Chinese manufacturers are leading in humanoid robot shipments, with significant contracts and production milestones achieved in 2025 [30] Group 6: Intelligent Driving - Domestic policies are expected to facilitate the commercialization of L3 autonomous driving in 2026, with several manufacturers preparing to launch L3 models [32][33] - Tesla's Full Self-Driving (FSD) technology is setting the direction for autonomous driving, with significant advancements in AI capabilities [35] Group 7: Energy Storage - The expansion of AI computing power in North America is driving electricity demand, with domestic power equipment expected to accelerate exports [37][40] - China's "14th Five-Year Plan" includes significant investments in the power grid and energy storage, creating a favorable environment for industry growth [40][43] Group 8: Chemicals - The chemical industry is undergoing a transformation driven by policies aimed at supply-side reform, with a focus on optimizing supply structures and reducing excess capacity [44][47] - New economic sectors are boosting demand for chemical materials, particularly in AI, renewable energy, and robotics, leading to a favorable outlook for new materials [47][48]

Group 1: AI Applications - The global AI competition is intensifying, with significant capital expenditures from tech giants expected to lead to deeper application scenarios in 2026 [1][2] - The competitive landscape for AI applications is shifting from a dominance of OpenAI to a more multipolar environment, with companies like Google and Meta making significant advancements [2] - Domestic AI applications are reaching a tipping point, with major tech companies accelerating their investments and model iterations, leading to a resonance between model development and application penetration [5] Group 2: AI Computing Power - Major cloud service providers in North America are projected to increase their capital expenditures significantly, with a combined guidance of approximately $598.7 billion for 2026, reflecting a 67% year-on-year growth [7][8] - Domestic companies are also ramping up capital expenditures and accelerating the iteration of local models, driven by the need for domestic chip performance improvements [7][8] Group 3: Storage - The demand for storage is entering a new super cycle driven by AI training and inference needs, with AI servers consuming 8-10 times more DRAM and NAND than traditional servers [12][13] - The supply-demand imbalance in the storage sector is expected to persist, with global storage prices rising over 40% in Q4 2025 [13][17] Group 4: Commercial Aerospace - Commercial aerospace is becoming a key battleground in US-China competition, with significant policy support and funding initiatives in place to accelerate the industry [20][21] - Domestic companies are achieving breakthroughs in satellite mass production and reusable rocket technologies, transitioning from technology validation to commercial scale [23] Group 5: Humanoid Robots - Major overseas companies like Tesla and FigureAI are ramping up production plans for humanoid robots, which is expected to benefit domestic component suppliers [25][28] - Chinese manufacturers are leading in humanoid robot shipments, with significant orders and production milestones achieved in 2025 [29] Group 6: Intelligent Driving - The rollout of policies in China is expected to facilitate the commercialization of L3 autonomous driving in 2026, with several manufacturers already launching L3 models [32][33] - Tesla's Full Self-Driving (FSD) technology continues to lead the market, with ongoing enhancements expected to drive the commercialization of Robotaxi services [32] Group 7: Energy Storage - The aging power grid in North America is creating opportunities for domestic power equipment exports, particularly in gas turbines and high-voltage equipment [36][37] - China's "14th Five-Year Plan" includes significant investments in the power grid and energy storage, with a focus on high-value areas [37] Group 8: Chemicals - The chemical industry is undergoing a transformation driven by supply-side reforms, with a focus on optimizing supply structures and reducing excess capacity [41][43] - New economic sectors are driving demand for chemical materials, particularly in AI, renewable energy, and robotics, which are expected to sustain high demand in 2026 [43][46]

Core Insights - The strong resurgence of Hong Kong IPOs in 2025 is a central theme for the global capital markets, with nearly HKD 300 billion raised, reclaiming the top position in global IPO fundraising [2][7] - The Hong Kong IPO market has experienced a significant increase in both quantity and quality, with new listings up nearly 70% year-on-year and fundraising doubling compared to the previous year [2][3] Market Dynamics - The traditional dominance of internet and financial real estate sectors has been disrupted, with hard technology, advanced manufacturing, and biomedicine emerging as the three main pillars supporting the market [3][4] - Key sectors such as new energy, semiconductors, smart vehicles, and high-end equipment are now prominently represented in the Hong Kong market, enhancing its manufacturing base [3][4] Notable IPOs - Significant companies that went public in 2025 include: - CATL (宁德时代), raising approximately HKD 41 billion with a market cap of about HKD 920 billion and a PE ratio of around 18x [3] - Hengrui Medicine (恒瑞医药), a leader in innovative drugs, with a market cap of approximately HKD 320 billion and a PE of about 32x [3] - Sanhua Intelligent Control (三花智控), with a market cap of around HKD 180 billion and a PE of about 24x [3] - Haitian Flavoring and Food (海天味业), with a market cap of approximately HKD 420 billion and a PE of about 30x [3] - Chery Automobile (奇瑞汽车), with a market cap of around HKD 190 billion and a PE of about 12x [4] A+H Listing Trend - 2025 marked a significant year for A+H dual listings, with leading companies opting for this model to enhance global liquidity and valuation recovery [5][6] - The A+H model has become a standard for industry giants, reinforcing Hong Kong's position as the preferred overseas listing location for Chinese enterprises [6] Future Outlook - The recovery of the Hong Kong IPO market is seen as a result of multiple cyclical factors, including improved global liquidity, long-term valuation recovery, and the increasing demand for high-quality assets from mainland China [6][7] - Moving forward, the focus of the Hong Kong IPO market is expected to shift from quantity expansion to quality prioritization, with a stronger emphasis on industry logic over speculative trading [6][7]

Core Viewpoint - The article emphasizes the transition of China's economy into a new phase starting in 2026, focusing on total factor productivity and the capital market's role as a resource allocation engine rather than just a financing tool [3][12]. Investment Opportunities - Future investment opportunities are rooted in two main aspects: the resilience of industrial upgrades and the benefits of capital market reforms, particularly in shareholder returns [3][12]. - The article identifies three key sectors for investment in 2026: pharmaceuticals, technology, and advanced manufacturing [4][13]. Pharmaceuticals - The pharmaceutical industry is expected to see clearer innovation-driven and global competition trends, with a focus on Chinese innovative drug companies that have established strong technology platforms and successful international cases in areas like ADC and dual antibodies [4][13]. Technology - In the technology sector, AI models are evolving from mere tools to ecosystem builders, with increasing monetization capabilities. The focus in the Chinese market is on the progress of AI hardware localization, with expectations for more mature AI edge products by 2026 [4][13]. Advanced Manufacturing - The advanced manufacturing sector, particularly in humanoid robotics, is transitioning from thematic investment to performance verification, with a focus on companies that have established competitive advantages in products, technology, and customer relationships [5][14]. - In the smart vehicle sector, the emphasis is on leading companies with high barriers to entry and strong global competitiveness, especially in batteries and glass, while closely monitoring developments in smart driving technology [5][14]. Market Trends - The Chinese capital market is experiencing structural differentiation as it recovers from the bottom, with a shift from valuation recovery to profit growth driving market trends in 2026 [15]. - The article advocates for a disciplined approach to value investing, suggesting that the best opportunities often arise from contrarian views in volatile markets [15].

依据恒生指数有限公司检讨结果，本公司还将获选纳入多项恒生指数系列成份股，包括恒生综合中小型 股指数、恒生综合小型股指数、恒生小型股(可投资)指数、恒生港股通中国内地公司指数、恒生港股通 中小型股指数、恒生港股通小型股指数、恒生港股通创新药指数、恒生港股通创新药精选指数、恒生港 股通药品及生物技术(可投资)指数、恒生综合行业指数 - 医疗保健业、恒生医疗保健指数。 董事会认为，此次公司股票获选纳入多项重要指数，体现投资者对公司价值与成长潜力的认可，预期将 提升公司股票流动性、扩大持股人群、增加股东类型的多样性，有利于公司的长远稳定发展。董事会谨 此感谢股东及投资者的持续支持，本公司将深化在RAS赛道的领先优势及其他创新药领域的国际竞争 力，以深耕的研发优势驱动与时俱进的产业价值创造，实现市场开拓与社会责任的协同共赢。 智通财经APP讯，劲方医药-B(02595)发布公告，依据恒生指数有限公司于2026年2月13日公布的恒生指 数系列季度检讨结果，本公司入选恒生综合指数(HSCI)、恒生港股通指数以及恒生创新药指数等系列成 分股。该调整将于2026年3月9日正式生效。此外，摩根士丹利资本国际指数(MSCI)近日宣 ...

Group 1 - The stock price of TIDE Pharmaceutical (03880.HK) increased by 8.77% to close at HKD 26.30, driven by the overall strength of the Hong Kong pharmaceutical sector and positive company fundamentals [1] - TIDE Pharmaceutical's stock opened at HKD 24.20, reached a high of HKD 26.60, with a trading range of 9.93%. The Hong Kong pharmaceutical sector was active, with peers like Baijie Pharmaceutical-B rising over 8% and Zai Lab increasing over 6% [2] - The company focuses on peptide CDMO business, serving clients in over 50 countries with a client retention rate exceeding 90%. The financial report for the first half of 2025 showed a revenue increase of 28.52% year-on-year and a 101.71% increase in profit attributable to shareholders, supported by growing demand for GLP-1 related drug development [3] Group 2 - The innovation drug sector's valuation has adjusted to a relatively low level, with the Hong Kong innovation drug index valuation falling to the 24th percentile over the past five years, attracting capital back into the market. Policy emphasis on "domestic demand as the main driver" has boosted expectations for the pharmaceutical industry [3] - The current price-to-earnings ratio (TTM) for TIDE Pharmaceutical is 30.75 times, which is higher than the average level of the Hong Kong pharmaceutical sector, necessitating attention to the sustainability of earnings and valuation alignment [4] - The competitive landscape in the GLP-1 sector is intensifying, with a dense pipeline of research and development. The expiration of the semaglutide patent in 2026 may lead to a concentration of generic drug launches, potentially squeezing profit margins [4]

Macro Perspective - Since 2025, China's economy has increasingly shown characteristics of "new and superior" development, with new productive forces being cultivated and diverse consumer preferences becoming more prominent[3] - High-tech manufacturing PMI was 52.0% in January 2026, consistently outperforming the overall manufacturing PMI of 49.3%[21] - High-tech industries' added value grew by 11.0% year-on-year in December 2025, exceeding the overall industrial enterprises' growth by 5.8 percentage points[21] Industry Perspective - Investment in advanced manufacturing, such as aerospace and automotive, grew by 16.9% and 11.7% respectively, outpacing overall manufacturing investment growth[25] - The information technology service sector saw an investment increase of 28.4%, maintaining over 25% growth for 11 consecutive months[25] - The revenue growth of strategic emerging services was 9.9%, while high-tech services grew by 8.6%, both surpassing the overall service sector growth of 7.8%[24] Market Perspective - As of January 2026, the market capitalization weight of the A-share information and communication sector reached 24%, surpassing financial and real estate sectors at 19%[3] - The market capitalization of A-share new economy MAG7 stocks is below that of US MAG7 stocks (20%+) and Hong Kong stocks (10+%), indicating room for growth[3] - The performance of A-share strategic emerging industries showed a profit growth of 15.5%, exceeding the overall non-financial A-share sector's growth of 13.8%[38] Outlook and Risks - The transition from old to new economic drivers is expected to accelerate, positioning new economic sectors as the main growth engine for China's economy[3] - Key investment areas include technology innovation and advanced manufacturing, particularly in AI and innovative pharmaceuticals[3] - Risks include potential market learning effects, unexpected tightening of macro and industrial policies, and significant changes in macroeconomic conditions and liquidity[3]

Core Viewpoint - The article emphasizes the importance of "long-term" and "contrarian" investment strategies, focusing on the essence of business and long-term trends rather than short-term market emotions and price trends [1][2]. Group 1: Investment Strategy - The company prioritizes finding investment opportunities with asymmetric risk-reward characteristics, specifically those that are significantly undervalued, rather than merely low-priced or low PB/PE stocks [2][3]. - Successful contrarian investment opportunities should not only be undervalued but also have a strong potential for future recognition and appreciation [2][3]. Group 2: Market Dynamics - Significant price discrepancies often arise from the market's tendency to linear extrapolate past performance, while the actual business environment may experience nonlinear changes [3][5]. - Historical examples illustrate how market expectations can lag behind actual industry performance, leading to substantial investment opportunities when the market eventually corrects its views [4][5]. Group 3: Value Drivers - Two key conditions for identifying attractive investment opportunities are: 1) a significant expectation gap where the market currently does not recognize the potential, and 2) strong value tension that will compel future recognition [3][7]. - The article highlights that strong value tension arises from powerful industry trends, excellent business fundamentals, and efficient operations, which together create a compelling investment case [9][12]. Group 4: Current Market Outlook - The biopharmaceutical market is expected to experience a recovery, with growth rates projected to improve from nearly zero to 1.2-1.4 times GDP growth, driven by easing pressures from social deflation and the adaptation to DRG policies [14][15]. - Despite the need to lower return expectations due to previous valuation recoveries, the overall outlook remains optimistic, particularly for domestic innovative drugs, U.S. biotech stocks, and innovative medical devices [15][17]. Group 5: Future Growth Potential - The domestic innovative drug sector is anticipated to maintain strong growth over the next decade, with revenue expected to increase from over 100 billion to 1 trillion, indicating significant market potential [17]. - The U.S. biotech sector is entering a commercialization phase that could unlock new multi-billion dollar market opportunities, while domestic innovative high-value consumables also show promise for substantial growth [17].

经济观察报 记者 刘晓诺 2025年中国创新药的BD（业务拓展）交易很热，我认为这只是一个开始。2026年，中国BD的水平肯定要再提高一步。 第三，我们有4个药物已经在准备提交新药临床试验许可，都是独一无二的同类首创药物，预计将在2026—2027年陆续进入临床开发。 此外，我们也会争取做更好、更大的BD。不过这不是自己说了算的，BD最终还是要靠管线说话。从这个方面讲，维立志博迟早会做大交易。以后在BD方 面，维立志博也会是中国创新药行业里比较重要的力量。 2026年，创新药的每个领域都会有比较明显的进展，有两个领域进展可能更明显： 第一个是小核酸药物，对慢性病来说它的临床效果确实比较好。 第二个是TCE（T细胞衔接器，一种免疫治疗药物）。免疫检查点抑制剂的双抗、三抗药物，也会更进一步，但我认为TCE进步对行业来说更重要。以前 TCE药物对实体瘤的作用不强，今年可能会有进展。比如，在小细胞肺癌上，TCE药物非常明显地延长了患者的总生存期，这是ADC（抗体偶联药物）难以 做到的。 2026年，维立志博的重点工作主要有以下三项，其中前两项围绕我们的核心管线LBL-024，也就是PD-1/41BB双抗。现在抗肿瘤免 ...

Group 1 - The Chinese innovative drug industry has entered a critical stage of high-quality development, focusing on quality and core value rather than rapid scale expansion, moving from "barbaric growth" to "rational maturity" [2] - By 2026, the industry will emphasize core strengths and practical results, with a focus on producing valuable innovative outcomes and achieving efficient transformation [2] - Currently, the internationalization of Chinese innovative drugs is still in its early stages, with more early-stage pipelines engaging in license-out collaborations with multinational corporations (MNCs), reflecting global recognition of China's R&D capabilities [2] Group 2 - Innovative drug companies must adhere to their original intentions, focusing on unmet clinical needs rather than merely catering to business development transactions, with a goal to achieve FIC/BIC innovations to build core competitiveness [3] - Companies venturing abroad need to solidify their global capabilities by establishing a comprehensive self-operated system across R&D, production, commercialization, and regulatory compliance [3] - The new medical insurance directory and the first commercial insurance innovative drug directory are expected to enhance the accessibility of high-priced drugs and stabilize market expectations for companies [3] Group 3 - There is an opportunity for deep integration of digitalization and innovative drugs, with AI becoming a crucial tool for overcoming innovation bottlenecks and improving efficiency while reducing costs across various stages [4] - By 2026, the innovative drug industry will face both opportunities and challenges, with increasing industry concentration and a landscape where leading companies and niche leaders emerge [4] - The company aims to participate in the construction of the industry ecosystem by focusing on patient-centered approaches, aligning with innovation trends, ensuring compliance, and expanding collaboratively [4]